In the long and often dispiriting quest to cure cancer, the 1998 approval of the drug Herceptin was a tremendously hopeful moment. This drug for breast cancer was the first to use a tumor-specific ...
The regulatory landscape for drug evaluation is shifting. For digital twins and in silico trials to become reliable evidence for drug approvals, these digital tools will require input from regulators ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results